
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 12, 2021

IMMUNOVANT, INC.
(Exact name of Registrant as specified in its Charter)

Delaware
(State or other jurisdiction of incorporation or organization)

001-38906
(Commission File Number)

83-2771572
(IRS Employer Identification No.)

320 West 37th Street
New York, NY
(Address of principal executive offices)

10018
(Zip Code)

Registrant's telephone number, including area code: (917) 580-3099

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	IMVT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On November 12, 2021, Immunovant, Inc. issued a press release that it will provide a presentation regarding its business at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021. Copies of the press release and the presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the SEC made by Immunovant, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated November 12, 2021.
99.2	Presentation, dated November 17, 2021.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

NEW YORK, Nov. 12, 2021 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021.

Stifel 2021 Virtual Healthcare Conference Presentation

Date: Wednesday, November 17th, 2021

Time: 2:00pm Eastern Time

Webcast: The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company's website, located at www.immunovant.com

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com





Stifel 2021 Virtual Healthcare Conference



Investor Presentation
November 17, 2021



For Investor Audiences Only

Forward-looking statements

This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “future,” “potential,” “continue” and other similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. For example, forward-looking statements include statements Immunovant makes regarding its business strategy, its plans to develop and commercialize its product candidates, the potential safety and efficacy of Immunovant’s current or future product candidates, including batoclimab for Myasthenia Gravis, Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia, its expectations regarding timing, the design and results of clinical trials of its product candidates, Immunovant’s plans and expected timing with respect to regulatory filings and approvals, the size and growth potential of the markets for Immunovant’s product candidates, and its ability to serve those markets. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others: initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the timing of the commencement of additional clinical trials and resumption of current trials; Immunovant’s scientific approach, clinical trial design, indication selection and general development progress; future clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this presentation; any product candidates that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of the ongoing COVID-19 pandemic on Immunovant’s clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval and commercialization of its sole product candidate, IMVT-1401 (“batoclimab”); Immunovant is at an early stage in development of batoclimab; and Immunovant will require additional capital to fund its operations and advance batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed with the SEC on November 5, 2021. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.



Rethinking possibilities in autoimmune disease

Our vision: Normal lives for people with autoimmune diseases



**Love
Trailblazing**



**Bolder
Faster**



**All
Voices**



Anti-FcRn Market: Potential therapeutic benefit across wide range of indications

Fifteen indications announced by at least one anti-FcRn program



NEUROLOGY

Myasthenia Gravis

Chronic inflammatory demyelinating polyneuropathy
Myositis
Autoimmune encephalitis
Myelin oligodendrocyte glycoprotein antibody disorders (MOG-antibody disorder)



DERMATOLOGY

Bullous pemphigoid
Pemphigus foliaceus/
Pemphigus vulgaris



HEMATOLOGY

Warm autoimmune hemolytic anemia

Hemolytic disease of the fetus and newborn
Idiopathic thrombocytopenic purpura




RHEUMATOLOGY

Primary Sjögrens Syndrome
Lupus Nephritis
Systemic lupus erythematosus
Rheumatoid arthritis



ENDOCRINOLOGY

Thyroid eye disease



Broad approach to understanding patient insights for Myasthenia Gravis (MG)

Multi-pronged methodology



In-depth Interviews



Patient Advisory Council



Online Survey



Digital Community Insights

People with MG recognize limitations of current therapies, which keep them from living their normal lives

MG patient research feedback

Historical standards of care have important limitations

Episodic or cyclical treatment
– especially steroids and IvIg

Prolonged time to onset for
other immunosuppressants

Potential trade-offs to achieve therapeutic benefit

Potential safety concerns

Some invasive with
burdensome route of
administration


As medications adjusted, anxiety about flares remain

Desire confidence in ability
to sustain an adequate
response

Fear of flare may limit
patients' outlook of the future

Nearly 80% of people with MG (on treatment) reported moderate or major lifestyle modifications

MG patient survey feedback



Source: MG Patient Survey (n=50). Q: What is the extent of lifestyle modifications you make around your myasthenia gravis?

For Investor Audiences Only

94% of MG patients surveyed preferred a chronic versus intermittent dosing approach

MG patient survey feedback

94%

Chronic Dosing:

"I want to stay on my MG treatment, even when my symptoms are under control, so that I can maintain a response and avoid potential symptom flares"

"It's easier to schedule life around something so consistent"



6%

Intermittent Dosing:

"I only want MG treatment intermittently when my symptoms flare"



Source: Analysis – MG Patient Quantitative Survey (n=50)

Batoclimab's (IMVT-1401) differentiated attributes provide a unique opportunity to address patients' unmet needs



Reliable treatment options



Flexible treatment options



People-centered delivery of treatment



Significant impact on quality of life

Batoclimab

Flexible dosing potential:

Deep, rapid IgG suppression in the short-term; adjustable IgG suppression in the long-term

Subcutaneous route of administration:

Designed and developed for simple subcutaneous injection to provide human-centric, give and go dosing experience



For Investor Audiences Only

